Condition
Brugada Syndrome (BrS)
Total Trials
5
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Not Yet Recruiting2
Recruiting2
Enrolling By Invitation1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07364656Not ApplicableNot Yet RecruitingPrimary
Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors
NCT02413450Enrolling By Invitation
Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
NCT07146880Phase 2Not Yet RecruitingPrimary
Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
NCT06988189Recruiting
Unmasking Concealed Arrhythmia Syndromes
NCT06647927RecruitingPrimary
GenLab: Unveiling the Genetic Landscape of Brugada Syndrome: Novel Biomarker Discovery for Precise Diagnosis
Showing all 5 trials